<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DEXMEDETOMIDINE HYDROCHLORIDE - dexmedetomidine hydrochloride injection, solution </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Dexmedetomidine Hydrochloride Injection safely and effectively. See full prescribing information for Dexmedetomidine Hydrochloride Injection.<br><br>Dexmedetomidine Hydrochloride Injection<br>For intravenous use.<br>Initial U.S. Approval: 1999</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Dexmedetomidine Hydrochloride Injection is a relatively selective alpha<span class="Sub">2</span>-adrenergic agonist indicated for: </p>
<ul class="Disc"><li> Sedation of non-intubated patients prior to and/or during surgical and other procedures. (<a href="#b6b95c48-5af4-4229-bf8e-04f2a247da37">1.1</a>)</li></ul>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc">
<li>Individualize and titrate Dexmedetomidine Hydrochloride Injection dosing to desired clinical effect. (<a href="#c2f78897-e1b7-4639-9cb6-8b21b0e1990f">2.1</a>)</li>
<li>Administer Dexmedetomidine Hydrochloride Injection using a controlled infusion device. (<a href="#c2f78897-e1b7-4639-9cb6-8b21b0e1990f">2.1</a>)</li>
<li>Dilute the 200 mcg/2 mL (100 mcg/mL) vial contents in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration. (<a href="#dfd232d9-b4d0-4cf1-99d1-8d826efc82f6">2.4</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">For Adult Procedural Sedation:</span> Generally initiate at one mcg/kg over 10 <span class="Bold">minutes</span>, followed by a maintenance infusion initiated at 0.6 mcg/kg/<span class="Bold">hour</span> and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/<span class="Bold">hour</span>. (<a href="#e4a02298-9617-489e-bb2e-47040b2af139">2.2</a>) </p>
<p class="Highlighta"><span class="Bold">Alternative Doses:</span> Recommended for patients over 65 years of age and awake fiberoptic intubation patients. (<a href="#e4a02298-9617-489e-bb2e-47040b2af139">2.2</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Dexmedetomidine Hydrochloride Injection, 200 mcg (dexmedetomidine)/2 mL [100 mcg (dexmedetomidine)/mL] in a glass vial.  To be used after dilution. (<a href="#fdd80c3a-2e26-4696-adfe-7961d863864b">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None. (<a href="#ad85160c-5f1a-4c0f-8e32-3c19c117e5b4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Monitoring: Continuously monitor patients while receiving Dexmedetomidine Hydrochloride Injection. <a href="#f586a3a6-b39a-4952-aa07-f09cfc91cfa4">(5.1)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> and <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">Sinus Arrest</span>: Have occurred in young healthy volunteers with high vagal tone or with different routes of administration, e.g., rapid intravenous or bolus administration. <a href="#aca1ce9d-3571-4104-978b-bb3973b9a9b6">(5.2)</a>
</li>
<li> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>: May necessitate medical intervention. May be more pronounced in patients with <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, or chronic <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and in the elderly. Use with caution in patients with advanced <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> or severe ventricular dysfunction. <a href="#aca1ce9d-3571-4104-978b-bb3973b9a9b6">(5.2)</a>
</li>
<li>Co-administration with Other Vasodilators or Negative Chronotropic Agents: Use with caution due to additive pharmacodynamic effects. <a href="#aca1ce9d-3571-4104-978b-bb3973b9a9b6">(5.2)</a>
</li>
<li>Transient <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>: Observed primarily during the loading dose. Consider reduction in loading infusion rate. <a href="#ee4d3dec-636a-475d-b05f-34b88a662669">(5.3)</a>
</li>
<li>Arousability: Patients can become aroused/alert with stimulation; this alone should not be considered as lack of efficacy. <a href="#c111af44-e6b5-460e-a2f1-771e3226233d">(5.4)</a>
</li>
<li>Prolonged exposure to dexmedetomidine beyond 24 hours may be associated with tolerance and <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">tachyphylaxis</span> and a dose-related increase in adverse events. <a href="#feb21209-f21a-4d83-a25c-d4974207351c">(5.6)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc"><li>The most common adverse reactions (incidence greater than 2%) are <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>. <a href="#d81cd8c3-cdee-485c-a4f9-5d82922002b1">(6.1)</a>
</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC, Vigilance &amp; Medical Affairs at 1-800-551-7176 or FDA at 1-800-FDA-1088</span> <span class="Bold">or</span> <span class="Bold"><span class="Italics">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Anesthetics, Sedatives, Hypnotics, Opioids: Enhancement of pharmacodynamic effects. Reduction in dosage of Dexmedetomidine Hydrochloride Injection or the concomitant medication may be required. (<a href="#acb76028-f613-4f84-91c9-83b01191c95b">7.1</a>) </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Geriatric Patients: Dose reduction should be considered. (<a href="#e4a02298-9617-489e-bb2e-47040b2af139">2.2</a>, <a href="#d80fb59c-d0dd-4e1e-bd79-e91f986536c5">2.3</a>, <a href="#f586a3a6-b39a-4952-aa07-f09cfc91cfa4">5.1</a>, <a href="#c82b3357-788d-48a4-9a9b-ef28f49ff339">8.5</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Dose reduction should be considered. (<a href="#c2f78897-e1b7-4639-9cb6-8b21b0e1990f">2.1</a>, <a href="#e4a02298-9617-489e-bb2e-47040b2af139">2.2</a>, <a href="#d80fb59c-d0dd-4e1e-bd79-e91f986536c5">2.3</a>, <a href="#f0f2ad58-0dba-47ec-85ab-80d38933a6f0">5.7,</a>  <a href="#f829db4b-3bf5-40de-8bfa-2353c09cd15b">8.6</a>)</li>
<li>Pregnancy: Based on animal data, may cause fetal harm. (<a href="#c40b3126-ec79-40dd-918f-1a5d3b8805b7">8.1</a>)</li>
<li>Nursing Mothers: Caution should be exercised when administered to a nursing woman. (<a href="#ed10b54a-00ca-4b49-88f3-393b0a24bf5b">8.3</a>)   </li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 12/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Procedural Sedation</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Guidelines</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage Information</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosage Adjustment</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Preparation of Solution</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Administration with Other Fluids</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Compatibility with Natural Rubber</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Drug Administration</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">Sinus Arrest</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Transient <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Arousability</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Withdrawal</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Tolerance and <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">Tachyphylaxis</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Anesthetics, Sedatives, Hypnotics, Opioids</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Neuromuscular Blockers</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-13.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Procedural Sedation</a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="e4bbe5e0-9a5d-44f2-a31e-d8b40952ad52"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="34067-9">
<a name="b6b95c48-5af4-4229-bf8e-04f2a247da37"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Procedural Sedation</h2>
<p class="First">                  Dexmedetomidine Hydrochloride Injection is indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b1eb957b-f6c5-4959-ba17-376bafa5e010"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="34068-7">
<a name="c2f78897-e1b7-4639-9cb6-8b21b0e1990f"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Guidelines</h2>
<ul class="Disc">
<li>Dexmedetomidine Hydrochloride Injection dosing should be individualized and titrated to desired clinical response.</li>
<li>Dexmedetomidine Hydrochloride Injection is not indicated for infusions lasting longer than 24 hours.</li>
<li>Dexmedetomidine Hydrochloride Injection should be administered using a controlled infusion device.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="e4a02298-9617-489e-bb2e-47040b2af139"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage Information</h2>
<p class="First"><span class="Bold"><span class="Italics"> </span>Table 1: Dosage Information</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" valign="top"> <br><span class="Bold">INDICATION</span><br> <br><br>
</td>
<td class="Rrule" align="left" valign="top"> <br><span class="Bold">DOSAGE AND ADMINISTRATION</span><br> <br><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="top"> <br><span class="Bold">Initiation of Procedural Sedation</span><br> <br><br>
</td>
<td class="Rrule" align="left" valign="top"> <br><span class="Bold">For adult patients: </span>a loading infusion of one mcg/kg over 10 <span class="Bold">minutes</span>. For less invasive procedures such as ophthalmic surgery, a loading infusion of 0.5 mcg/kg given over 10 <span class="Bold">minutes</span> may be suitable. <br> <br><span class="Bold">For awake fiberoptic intubation in adult patients: </span>a loading infusion of one mcg/kg over 10 <span class="Bold">minutes</span>. <br><br><span class="Bold">For patients over 65 years of age:<span class="Italics">  </span></span>a loading infusion of 0.5 mcg/kg over 10 <span class="Bold">minutes</span> [<span class="Italics"><span class="Italics">see </span></span><span class="Italics"><span class="Italics"><a href="#c82b3357-788d-48a4-9a9b-ef28f49ff339">Use in Specific Populations (8.5)</a></span></span>]. <br><br><span class="Bold">For adult patients with impaired hepatic function: </span>a dose reduction should be considered [<span class="Italics"><span class="Italics">see <a href="#f829db4b-3bf5-40de-8bfa-2353c09cd15b">Use in Specific Populations (8.6)</a>, <a href="#d359c395-271f-4230-9587-075cc19b2f5a">Clinical Pharmacology (12.3)</a></span></span>]<span class="Italics"><span class="Italics">.</span></span><br><br><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top"> <br><span class="Bold">Maintenance of Procedural Sedation</span><br> <br><br>
</td>
<td class="Rrule" align="left" valign="top"> <br><span class="Bold">For adult patients: </span>the maintenance infusion is generally initiated at 0.6 mcg/kg/<span class="Bold">hour</span> and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/<span class="Bold">hour</span>.  The rate of the maintenance infusion should be adjusted to achieve the targeted level of sedation. <br> <br><span class="Bold">For awake fiberoptic intubation in adult patients: </span>a maintenance infusion of 0.7 mcg/kg/<span class="Bold">hour</span> is recommended until the endotracheal tube is secured. <br><br><span class="Bold">For patients over 65 years of age: </span>a dose reduction should be considered [<span class="Italics"><span class="Italics">see <a href="#c82b3357-788d-48a4-9a9b-ef28f49ff339">Use in Specific Populations (8.5)</a></span></span>]<span class="Italics"><span class="Italics">.</span></span><br><br><span class="Bold">For adult patients with impaired hepatic function: </span>a dose reduction should be considered [<span class="Italics"><span class="Italics">see <a href="#f829db4b-3bf5-40de-8bfa-2353c09cd15b">Use in Specific Populations (8.6)</a>, </span></span><span class="Italics"><span class="Italics"><a href="#d359c395-271f-4230-9587-075cc19b2f5a">Clinical Pharmacology (12.3)</a></span></span>]<span class="Italics"><span class="Italics">.</span></span><br><br><br>
</td>
</tr>
</tbody></table>
<br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="d80fb59c-d0dd-4e1e-bd79-e91f986536c5"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosage Adjustment</h2>
<p class="First">Due to possible <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span>, a reduction in dosage of Dexmedetomidine Hydrochloride Injection or other concomitant anesthetics, sedatives, hypnotics or opioids may be required when co-administered [<span class="Italics"><span class="Italics">see </span></span><span class="Italics"><span class="Italics"><a href="#acb76028-f613-4f84-91c9-83b01191c95b">Drug Interactions (7.1)</a></span></span>]<span class="Italics"><span class="Italics">.</span></span></p>
<p>Dosage reductions may need to be considered for <span class="Bold">adult </span>patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and geriatric patients [<span class="Italics"><span class="Italics">see <a href="#f0f2ad58-0dba-47ec-85ab-80d38933a6f0">Warnings and Precautions (5.7)</a>, <a href="#f829db4b-3bf5-40de-8bfa-2353c09cd15b">Use in Specific Populations (8.6)</a>, </span></span><span class="Italics"><span class="Italics"><a href="#d359c395-271f-4230-9587-075cc19b2f5a">Clinical Pharmacology (12.3)</a></span></span>]<span class="Italics"><span class="Italics">.<br></span></span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dfd232d9-b4d0-4cf1-99d1-8d826efc82f6"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Preparation of Solution</h2>
<p class="First">Strict aseptic technique must always be maintained during handling of Dexmedetomidine Hydrochloride Injection.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p>Dexmedetomidine Hydrochloride Injection, 200 mcg/2 mL (100 mcg/mL) must be diluted with 0.9% sodium chloride injection to achieve required concentration (4 mcg/mL) prior to administration.  Preparation of solutions is the same, whether for the loading dose or maintenance infusion.</p>
<p>To prepare the infusion, withdraw 2 mL of Dexmedetomidine Hydrochloride Injection, and add to 48 mL of 0.9% sodium chloride injection to a total of 50 mL.  Shake gently to mix well.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="cf0f8ccd-86c1-45aa-9f7a-d6a4bbec51e9"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Administration with Other Fluids</h2>
<p class="First">Dexmedetomidine Hydrochloride Injection infusion should not be co-administered through the same intravenous catheter with blood or plasma because physical compatibility has not been established.</p>
<p>Dexmedetomidine Hydrochloride Injection has been shown to be incompatible when administered with the following drugs: amphotericin B, diazepam. </p>
<p>Dexmedetomidine Hydrochloride Injection has been shown to be compatible when administered with the following intravenous fluids:</p>
<ul class="Disc">
<li>0.9% sodium chloride in water</li>
<li>5% dextrose in water</li>
<li>20% mannitol </li>
<li>Lactated Ringer’s solution </li>
<li>100 mg/mL magnesium sulfate solution </li>
<li>0.3% potassium chloride solution</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="e4710217-275c-4f69-a6d8-c8e223080e33"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Compatibility with Natural Rubber</h2>
<p class="First">Compatibility studies have demonstrated the potential for absorption of Dexmedetomidine Hydrochloride Injection to some types of natural rubber.  Although Dexmedetomidine Hydrochloride Injection is dosed to effect, it is advisable to use administration components made with synthetic or coated natural rubber gaskets.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="fdd80c3a-2e26-4696-adfe-7961d863864b"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Dexmedetomidine Hydrochloride Injection, 200 mcg (dexmedetomidine)/2 mL [100 mcg (dexmedetomidine)/mL] in a glass vial. To be used after dilution.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ad85160c-5f1a-4c0f-8e32-3c19c117e5b4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="e9c302af-df3a-4ced-9e45-dfb7b9166fbb"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="f586a3a6-b39a-4952-aa07-f09cfc91cfa4"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Drug Administration</h2>
<p class="First">Dexmedetomidine Hydrochloride Injection should be administered only by persons skilled in the management of patients in the operating room setting.  Due to the known pharmacological effects of Dexmedetomidine Hydrochloride Injection, patients should be continuously monitored while receiving Dexmedetomidine Hydrochloride Injection.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="aca1ce9d-3571-4104-978b-bb3973b9a9b6"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">Sinus Arrest</span></h2>
<p class="First">Clinically significant episodes of <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">sinus arrest</span> have been reported with Dexmedetomidine Hydrochloride Injection administration in young, healthy adult volunteers with high vagal tone or with different routes of administration including rapid intravenous or bolus administration.</p>
<p>Reports of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> have been associated with Dexmedetomidine Hydrochloride Injection infusion.  If medical intervention is required, treatment may include decreasing or stopping the infusion of Dexmedetomidine Hydrochloride Injection, increasing the rate of intravenous fluid administration, elevation of the lower extremities, and use of pressor agents.  Because Dexmedetomidine Hydrochloride Injection has the potential to augment <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> induced by vagal stimuli, clinicians should be prepared to intervene.  The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone.  In clinical trials, glycopyrrolate or atropine were effective in the treatment of most episodes of Dexmedetomidine Hydrochloride Injection-induced <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.  However, in some patients with significant cardiovascular dysfunction, more advanced resuscitative measures were required.</p>
<p>Caution should be exercised when administering Dexmedetomidine Hydrochloride Injection to patients with advanced <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> and/or severe ventricular dysfunction.  Because Dexmedetomidine Hydrochloride Injection decreases sympathetic nervous system activity, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> may be expected to be more pronounced in patients with <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, or chronic <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and in elderly patients.</p>
<p>In clinical trials where other vasodilators or negative chronotropic agents were co-administered with Dexmedetomidine Hydrochloride Injection an additive pharmacodynamic effect was not observed.  Nonetheless, caution should be used when such agents are administered concomitantly with Dexmedetomidine Hydrochloride Injection.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ee4d3dec-636a-475d-b05f-34b88a662669"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Transient <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">Transient <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> has been observed primarily during the loading dose in association with the initial peripheral vasoconstrictive effects of Dexmedetomidine Hydrochloride Injection. Treatment of the transient <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> has generally not been necessary, although reduction of the loading infusion rate may be desirable.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="c111af44-e6b5-460e-a2f1-771e3226233d"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Arousability</h2>
<p class="First">Some patients receiving Dexmedetomidine Hydrochloride Injection have been observed to be arousable and alert when stimulated.  This alone should not be considered as evidence of lack of efficacy in the absence of other clinical signs and symptoms.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="f2cf0965-0631-4580-b7a8-4b1d9be5c375"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Withdrawal</h2>
<p class="First"><span class="Bold">Procedural Sedation</span></p>
<p>In adult subjects, withdrawal symptoms were not seen after discontinuation of short-term infusions of Dexmedetomidine Hydrochloride Injection (&lt; 6 hours).</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="feb21209-f21a-4d83-a25c-d4974207351c"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Tolerance and <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">Tachyphylaxis</span></h2>
<p class="First">Use of dexmedetomidine beyond 24 hours has been associated with tolerance and <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">tachyphylaxis</span> and a dose-related increase in adverse reactions [<span class="Italics"><span class="Italics">see </span></span><span class="Italics"><span class="Italics"><a href="#d81cd8c3-cdee-485c-a4f9-5d82922002b1">Adverse Reactions (6.1)</a></span></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="f0f2ad58-0dba-47ec-85ab-80d38933a6f0"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Since Dexmedetomidine Hydrochloride Injection clearance decreases with severity of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, dose reduction should be considered in patients with impaired hepatic function [<span class="Italics"><span class="Italics">see <a href="#e4a02298-9617-489e-bb2e-47040b2af139">Dosage and Administration (2.2)</a></span></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="dd95c77a-b744-4e9b-a57e-9b1376572ad4"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34084-4">
<a name="d81cd8c3-cdee-485c-a4f9-5d82922002b1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.</p>
<br><p>Use of Dexmedetomidine Hydrochloride Injection has been associated with the following serious adverse reactions:</p>
<br><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">sinus arrest</span> [<span class="Italics"><span class="Italics">see </span></span><span class="Italics"><span class="Italics"><a href="#aca1ce9d-3571-4104-978b-bb3973b9a9b6">Warnings and Precautions (5.2)</a></span></span>]</li>
<li>Transient <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> [<span class="Italics"><span class="Italics">see <a href="#ee4d3dec-636a-475d-b05f-34b88a662669">Warnings and Precautions (5.3)</a></span></span>]</li>
</ul>
<p>Most common treatment-emergent adverse reactions, occurring in greater than 2% of patients in procedural sedation studies include <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<br><p><span class="Bold">Procedural Sedation</span></p>
<br><p>Adverse reaction information is derived from the two trials for procedural sedation [<span class="Italics">see <a href="#fadac27c-9965-42ff-bbc4-b253a06ea65b">Clinical Studies (14.1)</a></span>] in which 318 adult patients received Dexmedetomidine Hydrochloride Injection. The mean total dose was 1.6 mcg/kg (range: 0.5 to 6.7), mean dose per hour was 1.3 mcg/kg/hr (range: 0.3 to 6.1) and the mean duration of infusion of 1.5 hours (range: 0.1 to 6.2).  The population was between 18 to 93 years of age, ASA I-IV, 30% ≥ 65 years of age, 52% male and 61% Caucasian.</p>
<br><p>Treatment-emergent adverse reactions occurring at an incidence of &gt; 2% are provided in Table 2.  The most frequent adverse reactions were <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> [<span class="Italics"><span class="Italics">see <a href="#aca1ce9d-3571-4104-978b-bb3973b9a9b6">Warnings and Precautions (5.2)</a></span></span>].  Pre-specified criteria for the vital signs to be reported as adverse reactions are footnoted below the table.  The decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> was similar between Dexmedetomidine Hydrochloride Injection and comparator groups in both studies.</p>
<p><span class="Bold">Table 2: Adverse Reactions with an Incidence &gt; 2%<span class="Bold">—</span>Procedural Sedation Population</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" valign="top">
<span class="Bold"><br><br><br><br>            Adverse Event</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Dexmedetomidine Hydrochloride Injection</span><br><span class="Bold"> </span><br><span class="Bold">(N = 318)</span><br><br>(%<br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Placebo</span><br> <br><span class="Bold">(N = 113)</span><br><br>(%)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span><span class="Sup">1</span><br><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span><span class="Sup">2</span><br> <br><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span><span class="Sup">3</span><br><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span><span class="Sup">4</span><br><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span><span class="Sup">5</span><br><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span><br><br><span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxia</span><span class="Sup">6</span><br><span class="product-label-link" type="condition" conceptid="4314808" conceptname="Slow respiration">Bradypnea</span><br>
</td>
<td class="Rrule" align="center" valign="top">54%<br>37%<br> <br>14%<br>13%<br>5%<br> <br>3%<br>3%<br><br> 2%<br>2%<br>
</td>
<td class="Rrule" align="center" valign="top">30%<br>32%<br> <br>4%<br>24%<br>17%<br> <br>2%<br> 1%<br><br> 3%<br>4%<br>
</td>
</tr>
</tbody></table>
<p><span class="Sup">1 </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> was defined in absolute and relative terms as Systolic blood pressure of &lt; 80 mmHg or ≤ 30% lower than pre-study drug infusion value, or Diastolic blood pressure of &lt; 50 mmHg.</p>
<br><p><span class="Sup">2</span> <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> was defined in absolute and relative terms as <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> (RR) &lt; 8 beats per minute or &gt; 25% decrease from baseline.</p>
<br><p><span class="Sup">3</span> <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> was defined in absolute and relative terms as &lt; 40 beats per minute or ≤ 30% lower than pre-study drug infusion value.</p>
<br><p><span class="Sup">4</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> was defined in absolute and relative terms as Systolic blood pressure &gt; 180 mmHg or ≥ 30% higher than pre-study drug infusion value or Diastolic blood pressure of &gt; 100 mmHg.</p>
<br><p><span class="Sup">5</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span> was defined in absolute and relative terms as &gt; 120 beats per minute or ≥ 30% greater than pre-study drug infusion value.</p>
<br><p><span class="Sup">6</span> <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxia</span> was defined in absolute and relative terms as SpO<span class="Sub">2</span> &lt; 90% or 10% decrease from baseline.</p>
<br>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d728d6b5-c1d7-4c9b-8243-45e633056cb7"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of Dexmedetomidine Hydrochloride Injection.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<br><p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> were the most common adverse reactions associated with the use of Dexmedetomidine Hydrochloride Injection during post approval use of the drug.</p>
<br><br><br><p><span class="Bold">Table 3: Adverse Reactions Experienced During Post-approval Use of Dexmedetomidine Hydrochloride Injection</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="588"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">System Organ Class </span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">Preferred Term </span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Blood and Lymphatic System Disorders <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span> <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">cardiac disorder</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span> <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4206763" conceptname="Photopsia">Photopsia</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">General Disorders and Administration Site Conditions <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Hepatobiliary Disorders <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Hepatic function abnormal</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Investigations <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> increased, blood alkaline phosphatase increased, blood urea increased, electrocardiogram T wave inversion, gammaglutamyltransferase increased <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Metabolism and Nutrition Disorders <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, speech disorder <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Psychiatric Disorders <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4238753" conceptname="Optical illusion">illusion</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Renal and Urinary Disorders <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span> <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">pulmonary congestion</span>, <span class="product-label-link" type="condition" conceptid="4048509" conceptname="Respiratory acidosis">respiratory acidosis</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Skin and Subcutaneous Tissue Disorders <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Surgical and Medical Procedures <br>
</td>
<td class="Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="4086497" conceptname="Light anesthesia">Light anesthesia</span> <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span> <br>
</td>
<td class="Rrule" valign="top">Blood pressure fluctuation, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <br>
</td>
</tr>
</tbody></table>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ed9596e7-8944-4d48-a431-f4ab9d91b9ce"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="acb76028-f613-4f84-91c9-83b01191c95b"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Anesthetics, Sedatives, Hypnotics, Opioids</h2>
<p class="First">Co-administration of Dexmedetomidine Hydrochloride Injection with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.  Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam.  No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> between Dexmedetomidine Hydrochloride Injection and isoflurane, propofol, alfentanil and midazolam have been demonstrated.  However, due to possible <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span>, when co-administered with Dexmedetomidine Hydrochloride Injection, a reduction in dosage of Dexmedetomidine Hydrochloride Injection or the concomitant anesthetic, sedative, hypnotic or opioid may be required.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="e642e4d8-7ef2-4604-9e52-9e550197d59c"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Neuromuscular Blockers</h2>
<p class="First">In one study of 10 healthy adult volunteers, administration of Dexmedetomidine Hydrochloride Injection for 45 minutes at a plasma concentration of one ng/mL resulted in no clinically meaningful increases in the magnitude of <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> associated with rocuronium administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="f493b442-f491-4858-b8e7-f1eac95f1791"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="c40b3126-ec79-40dd-918f-1a5d3b8805b7"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p>There are no adequate and well-controlled studies of Dexmedetomidine Hydrochloride Injection use in pregnant women.  In an <span class="Italics"><span class="Italics">in vitro</span></span> human placenta study, placental transfer of dexmedetomidine occurred.  In a study in the pregnant rat, placental transfer of dexmedetomidine was observed when radiolabeled dexmedetomidine was administered subcutaneously.  Thus, fetal exposure should be expected in humans, and Dexmedetomidine Hydrochloride Injection should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.</p>
<p>Teratogenic effects were not observed in rats following subcutaneous administration of dexmedetomidine during the period of fetal organogenesis (from gestation day 5 to 16) with doses up to 200 mcg/kg (representing a dose approximately equal to the maximum recommended human intravenous dose based on body surface area) or in rabbits following intravenous administration of dexmedetomidine during the period of fetal organogenesis (from gestation day 6 to 18) with doses up to 96 mcg/kg (representing approximately half the human exposure at the maximum recommended dose based on plasma area under the time-curve comparison).  However, fetal toxicity, as evidenced by increased post-implantation losses and reduced live pups, was observed in rats at a subcutaneous dose of 200 mcg/kg.  The no-effect dose in rats was 20 mcg/kg (representing a dose less than the maximum recommended human intravenous dose based on a body surface area comparison).  In another reproductive toxicity study when dexmedetomidine was administered subcutaneously to pregnant rats at 8 and 32 mcg/kg (representing a dose less than the maximum recommended human intravenous dose based on a body surface area comparison) from gestation day 16 through weaning, lower offspring weights were observed.  Additionally, when offspring of the 32 mcg/kg group were allowed to mate, elevated fetal and embryocidal toxicity and delayed motor development was observed in second generation offspring.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="bff1fc65-2757-4911-b156-3bfd995480bf"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The safety of Dexmedetomidine Hydrochloride Injection during labor and delivery has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ed10b54a-00ca-4b49-88f3-393b0a24bf5b"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether Dexmedetomidine Hydrochloride Injection is excreted in human milk. Radio-labeled dexmedetomidine administered subcutaneously to lactating female rats was excreted in milk.  Because many drugs are excreted in human milk, caution should be exercised when Dexmedetomidine Hydrochloride Injection is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="a14b89a2-1f88-4883-8135-a8261579f366"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy have not been established for Procedural Sedation in pediatric patients. Additional information describing clinical studies in a different indication in which efficacy was not demonstrated in pediatric patients is approved for Hospira’s dexmedetomidine injection. However, due to Hospira’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. The use of dexmedetomidine for procedural sedation in pediatric patients has not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="c82b3357-788d-48a4-9a9b-ef28f49ff339"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"><span class="Bold">Procedural Sedation</span></p>
<p>A total of 131 patients in the clinical studies were 65 years of age and over.  A total of 47 patients were 75 years of age and over.  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> occurred in a higher incidence in Dexmedetomidine Hydrochloride Injection-treated patients 65 years or older (72%) and 75 years or older (74%) as compared to patients &lt; 65 years (47%).  A reduced loading dose of 0.5 mcg/kg given over 10 minutes is recommended and a reduction in the maintenance infusion should be considered for patients greater than 65 years of age.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="f829db4b-3bf5-40de-8bfa-2353c09cd15b"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Since Dexmedetomidine Hydrochloride Injection clearance decreases with increasing severity of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, dose reduction should be considered in patients with impaired hepatic function [<span class="Italics"><span class="Italics">see <a href="#e4a02298-9617-489e-bb2e-47040b2af139">Dosage and Administration (2.2)</a> and </span></span><span class="Italics"><span class="Italics"><a href="#d359c395-271f-4230-9587-075cc19b2f5a">Clinical Pharmacology (12.3)</a></span></span>]<span class="Italics"><span class="Italics">.</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="ac713beb-abb9-44c5-ae2b-760a2ad7f1a3"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="edf164e6-1e27-4fe8-985e-f68fd70c355f"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">Dexmedetomidine hydrochloride is not a controlled substance.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="b55a2629-d05b-4dbc-a302-b7868b1311d4"></a><a name="section-9.2"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First"> The <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> potential of Dexmedetomidine Hydrochloride Injection has not been studied in humans.  However, since studies in rodents and primates have demonstrated that Dexmedetomidine Hydrochloride Injection exhibits pharmacologic actions similar to those of clonidine, it is possible that Dexmedetomidine Hydrochloride Injection may produce a clonidine-like withdrawal syndrome upon abrupt discontinuation [<span class="Italics"><span class="Italics">see <a href="#f2cf0965-0631-4580-b7a8-4b1d9be5c375">Warnings and Precautions (5.5)</a></span></span>]<span class="Italics"><span class="Italics">.</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="cca514bf-d7e2-485a-b77b-a59195b8fe8d"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The tolerability of Dexmedetomidine Hydrochloride Injection was studied in one study in which healthy adult subjects were administered doses at and above the recommended dose of 0.2 to 0.7 mcg/kg/hr.  The maximum blood concentration achieved in this study was approximately 13 times the upper boundary of the therapeutic range.  The most notable effects observed in two subjects who achieved the highest doses were <span class="product-label-link" type="condition" conceptid="314379" conceptname="First degree atrioventricular block">first degree atrioventricular block</span> and second degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>.  No hemodynamic compromise was noted with the <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span> and the <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> resolved spontaneously within one minute.</p>
<p>One patient who received a loading bolus dose of undiluted Dexmedetomidine Hydrochloride Injection (19.4 mcg/kg), had <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> from which he was successfully resuscitated.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="cecfc2cc-8fc8-4fff-9c91-f2bd84735514"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Dexmedetomidine Hydrochloride Injection is a sterile, nonpyrogenic solution suitable for intravenous infusion following dilution.  Dexmedetomidine hydrochloride is the S-enantiomer of medetomidine and is chemically described as (+)-4-(S)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole monohydrochloride, and the structural formula is: </p>
<p> <img alt="dexmed-structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c1b8eb58-596b-481d-beb6-ba9d2237abf4&amp;name=dexmed-structure.jpg"></p>
<p>Dexmedetomidine hydrochloride is a white or almost white powder that is freely soluble in water and has a pKa of 7.1.  Its partition coefficient in-octanol: water at pH 7.4 is 2.89. Dexmedetomidine Hydrochloride Injection is supplied as a clear, colorless, isotonic solution with a pH of 4.5 to 7.0.  Each mL contains 118 mcg of dexmedetomidine hydrochloride equivalent to 100 mcg (0.1 mg) of dexmedetomidine, 9 mg of sodium chloride, 597 mcg of sodium acetate trihydrate and 27 mcg of glacial acetic acid in water.  The solution is preservative-free.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="b44ee0d0-821b-40b0-8796-f6a0291fabf4"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="f3033c92-dd51-411d-bda9-4ce21225f4ee"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Dexmedetomidine Hydrochloride Injection is a relatively selective alpha<span class="Sub">2</span>-adrenergic agonist with sedative properties.  Alpha<span class="Sub">2</span> selectivity is observed in animals following slow intravenous infusion of low and medium doses (10 to 300 mcg/kg).  Both alpha<span class="Sub">1</span> and alpha<span class="Sub">2</span> activity is observed following slow intravenous infusion of high doses (≥ 1,000 mcg/kg) or with rapid intravenous administration.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="df945233-7eef-4fda-8049-d8f0914b381d"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">In a study in healthy volunteers (N = 10), <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and oxygen saturation remained within normal limits and there was no evidence of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> when Dexmedetomidine Hydrochloride Injection was administered by intravenous infusion at doses within the recommended dose range (0.2 to 0.7 mcg/kg/hr).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="d359c395-271f-4230-9587-075cc19b2f5a"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic parameters: a rapid distribution phase with a distribution half-life (t<span class="Sub">1/2</span>) of approximately 6 minutes; a terminal elimination half-life (t<span class="Sub">1/2</span>) of approximately 2 hours; and steady-state volume of distribution (V<span class="Sub">ss</span>) of approximately 118 liters.  Clearance is estimated to be approximately 39 L/h.  The mean body weight associated with this clearance estimate was 72 kg.</p>
<br><p>Dexmedetomidine exhibits linear pharmacokinetics in the dosage range of 0.2 to 0.7 mcg/kg/hr when administered by intravenous infusion for up to 24 hours.  Table 4 shows the main pharmacokinetic parameters when Dexmedetomidine Hydrochloride Injection was infused (after appropriate loading doses) at maintenance infusion rates of 0.17 mcg/kg/hr (target plasma concentration of 0.3 ng/mL) for 12 and 24 hours, 0.33 mcg/kg/hr (target plasma concentration of 0.6 ng/mL) for 24 hours, and 0.70 mcg/kg/hr (target plasma concentration of 1.25 ng/mL) for 24 hours.</p>
<br><br><br><p><span class="Bold"> Table 4: Mean ± SD Pharmacokinetic Parameters</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" rowspan="4" valign="top">
<span class="Bold"><br><br><br>            Parameter</span><br>
</td>
<td class="Rrule" align="center" colspan="4" valign="top"> <span class="Bold">Loading Infusion (min)/Total Infusion Duration (hrs)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <span class="Bold">10 min/12 hrs</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <span class="Bold">10 min/24 hrs</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">10 min/24 hrs</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">35 min/24 hrs</span><br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="center" colspan="4" valign="top">
<span class="Bold">Dexmedetomidine Hydrochloride Injection Target Plasma Concentration (ng/mL) </span><span class="Bold">and Dose (mcg/kg/hr)</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <span class="Bold">0.3/0.17</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">0.3/0.17</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">0.6/0.33</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">1.25/0.70</span><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top"> <span class="Bold">t<span class="Sub">1/2</span>*, hour </span><br> <br><span class="Bold">CL, liter/hour</span><br><br><span class="Bold">V<span class="Sub">ss</span>, liter </span><br><br><span class="Bold">Avg C<span class="Sub">ss</span><span class="Sup">#</span>, ng/mL </span><br>
</td>
<td class="Rrule" align="center" valign="top"> 1.78 ± 0.30<br> <br>46.3 ± 8.3<br><br>88.7 ± 22.9<br><br>0.27 ± 0.05<br>
</td>
<td class="Rrule" align="center" valign="top">2.22 ± 0.59<br> <br>43.1 ± 6.5<br><br>102.4 ± 20.3<br><br>0.27 ± 0.05<br>
</td>
<td class="Rrule" align="center" valign="top">2.23 ± 0.21<br> <br>35.3 ± 6.8<br><br>93.6 ± 17<br><br>0.67 ± 0.10<br>
</td>
<td class="Rrule" align="center" valign="top">2.50 ± 0.61<br> <br>36.5 ± 7.5<br><br>99.6 ± 17.8<br><br>1.37 ± 0.20<br>
</td>
</tr>
</tbody></table>
<p> * Presented as harmonic mean and pseudo standard deviation.</p>
<br><p><span class="Sup">#</span> Mean C<span class="Sub">ss</span> = Average steady-state concentration of Dexmedetomidine Hydrochloride Injection.  The mean C<span class="Sub">ss </span>was calculated based on post-dose sampling from 2.5 to 9 hours samples for 12 hour infusion and post-dose sampling from 2.5 to 18 hours for 24 hour infusions.</p>
<br><p>The loading doses for each of the above indicated groups were 0.5, 0.5, 1 and 2.2 mcg/kg, respectively.</p>
<br><p>Dexmedetomidine pharmacokinetic parameters after Dexmedetomidine Hydrochloride Injection maintenance doses of 0.2 to 1.4 mcg/kg/hr for &gt; 24 hours were similar to the PK parameters after Dexmedetomidine Hydrochloride Injection maintenance dosing for &lt; 24 hours in other studies.  The values for clearance (CL), volume of distribution (V), and t<span class="Sub">1/2 </span>were 39.4 L/hr, 152 L, and 2.67 hours, respectively.</p>
<br><p><span class="Bold">Distribution</span></p>
<br><p>The steady-state volume of distribution (V<span class="Sub">ss</span>) of dexmedetomidine was approximately 118 liters. Dexmedetomidine protein binding was assessed in the plasma of normal healthy male and female subjects.  The average protein binding was 94% and was constant across the different plasma concentrations tested.  Protein binding was similar in males and females.  The fraction of Dexmedetomidine Hydrochloride Injection that was bound to plasma proteins was significantly decreased in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to healthy subjects.</p>
<br><p>The potential for protein binding displacement of dexmedetomidine by fentanyl, ketorolac, theophylline, digoxin and lidocaine was explored <span class="Italics"><span class="Italics">in vitro</span></span>, and negligible changes in the plasma protein binding of Dexmedetomidine Hydrochloride Injection were observed.  The potential for protein binding displacement of phenytoin, warfarin, ibuprofen, propranolol, theophylline and digoxin by Dexmedetomidine Hydrochloride Injection was explored <span class="Italics"><span class="Italics">in vitro </span></span>and none of these compounds appeared to be significantly displaced by Dexmedetomidine Hydrochloride Injection.</p>
<br><p><span class="Bold">Metabolism</span></p>
<br><p>Dexmedetomidine undergoes almost complete biotransformation with very little unchanged dexmedetomidine excreted in urine and feces.  Biotransformation involves both direct glucuronidation as well as cytochrome P450 mediated metabolism.  The major metabolic pathways of dexmedetomidine are: direct N-glucuronidation to inactive metabolites; aliphatic hydroxylation (mediated primarily by CYP2A6) of dexmedetomidine to generate 3-hydroxy-dexmedetomidine, the glucuronide of 3-hydroxy-dexmedetomidine, and 3-carboxy-dexmedetomidine; and N-methylation of dexmedetomidine to generate 3-hydroxy N-methyl-dexmedetomidine, 3-carboxy N-methyl-dexmedetomidine, and dexmedetomidine-N-methyl O-glucuronide.</p>
<br><p><span class="Bold">Elimination</span></p>
<br><p>The terminal elimination half-life (t<span class="Sub">1/2</span>) of dexmedetomidine is approximately 2 hours and clearance is estimated to be approximately 39 L/h.  A <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study demonstrated that after nine days an average of 95% of the radioactivity, following intravenous administration of radiolabeled dexmedetomidine, was recovered in the urine and 4% in the feces.  No unchanged dexmedetomidine was detected in the urine.  Approximately 85% of the radioactivity recovered in the urine was excreted within 24 hours after the infusion.  Fractionation of the radioactivity excreted in urine demonstrated that products of N-glucuronidation accounted for approximately 34% of the cumulative urinary excretion.  In addition, aliphatic hydroxylation of parent drug to form 3-hydroxy-dexmedetomidine, the glucuronide of 3-hydroxy-dexmedetomidine, and 3-carboxylic acid-dexmedetomidine together represented approximately 14% of the dose in urine.  N-methylation of dexmedetomidine to form 3-hydroxy N-methyl dexmedetomidine, 3-carboxy N-methyl dexmedetomidine, and N-methyl O-glucuronide dexmedetomidine accounted for approximately 18% of the dose in urine.  The N-Methyl metabolite itself was a minor circulating component and was undetected in urine.  Approximately 28% of the urinary metabolites have not been identified.</p>
<br><p><span class="Bold">Gender</span></p>
<br><p>There was no observed difference in Dexmedetomidine Hydrochloride Injection pharmacokinetics due to gender.</p>
<p><span class="Bold">Geriatrics</span></p>
<br><p>The pharmacokinetic profile of Dexmedetomidine Hydrochloride Injection was not altered by age.  There were no differences in the pharmacokinetics of Dexmedetomidine Hydrochloride Injection in young (18 to 40 years), middle age (41 to 65 years), and elderly (&gt; 65 years) subjects.</p>
<br><p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </span></p>
<br><p>In subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class A, B, or C), clearance values for Dexmedetomidine Hydrochloride Injection were lower than in healthy subjects.  The mean clearance values for patients with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> were 74%, 64% and 53% of those observed in the normal healthy subjects, respectively.  Mean clearances for free drug were 59%, 51% and 32% of those observed in the normal healthy subjects, respectively.</p>
<br><p>Although Dexmedetomidine Hydrochloride Injection is dosed to effect, it may be necessary to consider dose reduction in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see </span> <span class="Italics"><span class="Italics"><a href="#e4a02298-9617-489e-bb2e-47040b2af139">Dosage and Administration (2.2)</a></span></span><span class="Italics"><span class="Italics">, Warnings and Precautions (<a href="#f0f2ad58-0dba-47ec-85ab-80d38933a6f0">5.7</a>)</span></span>].</p>
<br><p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<br><p>Dexmedetomidine Hydrochloride Injection pharmacokinetics (C<span class="Sub">max</span>, T<span class="Sub">max</span>, AUC, t<span class="Sub">1/2</span>, CL, and  V<span class="Sub">ss</span>) were not significantly different in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance: &lt; 30 mL/min) compared to healthy subjects.</p>
<br><p><span class="Bold">Drug Interactions</span></p>
<br><p><span class="Italics"><span class="Italics">In vitro </span></span>studies: <span class="Italics"><span class="Italics">In vitro </span></span>studies in human liver microsomes demonstrated no evidence of cytochrome P450 mediated drug interactions that are likely to be of clinical relevance.</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="a19962e5-473d-4a5a-85f7-8e669a091784"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="f49de8f3-386c-4844-b761-154ec81774a5"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Animal carcinogenicity studies have not been performed with dexmedetomidine.</p>
<p>Dexmedetomidine was not mutagenic <span class="Italics"><span class="Italics">in vitro</span></span>, in either the bacterial reverse mutation assay (<span class="Italics"><span class="Italics">E. coli </span></span>and <span class="Italics"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span></span>) or the mammalian cell forward mutation assay (mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>).  Dexmedetomidine was clastogenic in the <span class="Italics"><span class="Italics">in vitro </span></span>human lymphocyte chromosome aberration test with, but not without, rat S9 metabolic activation.  In contrast, dexmedetomidine was not clastogenic in the <span class="Italics"><span class="Italics">in vitro </span></span>human lymphocyte chromosome aberration test with or without human S9 metabolic activation.  Although dexmedetomidine was clastogenic in an <span class="Italics"><span class="Italics">in vivo </span></span>mouse micronucleus test in NMRI mice, there was no evidence of clastogenicity in CD-1 mice.</p>
<p>Fertility in male or female rats was not affected after daily subcutaneous injections of dexmedetomidine at doses up to 54 mcg/kg (less than the maximum recommended human intravenous dose on a mcg/m<span class="Sup">2</span> basis) administered from 10 weeks prior to mating in males, and 3 weeks prior to mating and during mating in females.</p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="db47ddad-978b-4d32-87f9-a80c5e78ed9a"></a><a name="section-13.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">There were no differences in the adrenocorticotropic hormone (ACTH)-stimulated cortisol response in dogs following a single dose of dexmedetomidine compared to saline control.  However, after continuous subcutaneous infusions of dexmedetomidine at 3 mcg/kg/hr and 10 mcg/kg/hr for one week in dogs (exposures estimated to be within the clinical range), the ACTH-stimulated cortisol response was diminished by approximately 27% and 40%, respectively, compared to saline-treated control animals indicating a dose-dependent adrenal suppression.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="d65ebc9e-7c5f-4503-9306-2eb189e5b46f"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of dexmedetomidine hydrochloride injection has been evaluated in two randomized, double-blind, placebo-controlled multicenter clinical trials in 431 adult patients.</p>
<div class="Section" data-sectionCode="34092-7">
<a name="fadac27c-9965-42ff-bbc4-b253a06ea65b"></a><a name="section-14.1"></a><p></p>
<h2>14.1 Procedural Sedation</h2>
<p class="First">The safety and efficacy of Dexmedetomidine Hydrochloride Injection for sedation of non-intubated patients prior to and/or during surgical and other procedures was evaluated in two randomized, double-blind, placebo-controlled multicenter clinical trials. Study 1 evaluated the sedative properties of Dexmedetomidine Hydrochloride Injection in patients having a variety of elective surgeries/procedures performed under monitored anesthesia care.  Study 2 evaluated Dexmedetomidine Hydrochloride Injection in patients undergoing awake fiberoptic intubation prior to a surgical or diagnostic procedure. </p>
<br><p>In Study 1, the sedative properties of Dexmedetomidine Hydrochloride Injection were evaluated by comparing the percent of patients not requiring rescue midazolam to achieve a specified level of sedation using the standardized Observer’s Assessment of Alertness/Sedation Scale (see Table 5). </p>
<br><p><span class="Bold"><span class="Italics"> </span>Table 5: Observer’s Assessment of Alertness/Sedation</span></p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="5" valign="top"> <span class="Bold">Assessment Categories</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <span class="Bold">Responsiveness</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <span class="Bold">Speech</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <span class="Bold">Facial </span><span class="Bold">Expression</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Eyes</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <span class="Bold">Composite Score</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">Responds readily to name spoken in normal tone<br>
</td>
<td class="Rrule" align="center" valign="top">Normal<br>
</td>
<td class="Rrule" align="center" valign="top">Normal<br>
</td>
<td class="Rrule" align="center" valign="top">Clear, no <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span><br>
</td>
<td class="Rrule" align="center" valign="top">5 (alert)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargic</span> response to name spoken in normal tone<br>
</td>
<td class="Rrule" align="center" valign="top"> Mild slowing or thickening<br>
</td>
<td class="Rrule" align="center" valign="top">Mild relaxation<br>
</td>
<td class="Rrule" align="center" valign="top"> Glazed or mild <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span> (less than half the eye)<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">Responds only after name is called loudly and/or repeatedly<br>
</td>
<td class="Rrule" align="center" valign="top"> Slurring or prominent slowing<br>
</td>
<td class="Rrule" align="center" valign="top"> Marked relaxation (slack jaw)<br>
</td>
<td class="Rrule" align="center" valign="top"> Glazed and marked <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span> (half the eye or more)<br>
</td>
<td class="Rrule" align="center" valign="top"> 3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top"> Responds only after mild prodding or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span><br>
</td>
<td class="Rrule" align="center" valign="top"> Few recognizable words<br>
</td>
<td class="Rrule" align="center" valign="top"> –<br>
</td>
<td class="Rrule" align="center" valign="top">–<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top"> Does not respond to mild prodding or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span><br>
</td>
<td class="Rrule" align="center" valign="top"> –<br>
</td>
<td class="Rrule" align="center" valign="top"> –<br>
</td>
<td class="Rrule" align="center" valign="top">–<br>
</td>
<td class="Rrule" align="center" valign="top"> 1 (deep sleep)<br>
</td>
</tr>
</tbody></table>
<br><p>Patients were randomized to receive a loading infusion of either Dexmedetomidine Hydrochloride Injection 1 mcg/kg, Dexmedetomidine Hydrochloride Injection 0.5 mcg/kg, or placebo (normal saline) given over 10 minutes and followed by a maintenance infusion started at 0.6 mcg/kg/hr.  The maintenance infusion of study drug could be titrated from 0.2 mcg/kg/hr to 1 mcg/kg/hr to achieve the targeted sedation score (Observer’s Assessment of Alertness/Sedation Scale ≤ 4).  Patients were allowed to receive rescue midazolam as needed to achieve and/or maintain an Observer’s Assessment of Alertness/Sedation Scale ≤ 4.  After achieving the desired level of sedation, a local or regional anesthetic block was performed.  Demographic characteristics were similar between the Dexmedetomidine Hydrochloride Injection and comparator groups.  Efficacy results showed that Dexmedetomidine Hydrochloride Injection was more effective than the comparator group when used to sedate non-intubated patients requiring monitored anesthesia care during surgical and other procedures (see Table 6).  </p>
<br><p>In Study 2, the sedative properties of Dexmedetomidine Hydrochloride Injection were evaluated by comparing the percent of patients requiring rescue midazolam to achieve or maintain a specified level of sedation using the Ramsay Sedation Scale score ≥ 2.  Patients were randomized to receive a loading infusion of Dexmedetomidine Hydrochloride Injection 1 mcg/kg or placebo (normal saline) given over 10 minutes and followed by a fixed maintenance infusion of 0.7 mcg/kg/hr.  After achieving the desired level of sedation, topicalization of the airway occurred.  Patients were allowed to receive rescue midazolam as needed to achieve and/or maintain a Ramsay Sedation Scale ≥ 2.  Demographic characteristics were similar between the Dexmedetomidine Hydrochloride Injection and comparator groups.  For efficacy results see Table 6.<span class="Bold"><br><br>Table 6: Key Efficacy Results of Procedural Sedation Studies</span></p>
<table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" valign="top"> <span class="Bold">Study</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Loading Infusion Treatment Arm</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <span class="Bold">Number of Patients Enrolled<span class="Sup">a</span></span><br>
</td>
<td class="Rrule" align="center" valign="top"> <span class="Bold">% Not Requiring Midazolam Rescue</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Confidence<span class="Sup">b  </span>Interval on the Difference vs. Placebo</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Mean (SD) Total Dose (mg) of Rescue Midazolam Required</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <span class="Bold">Confidence<span class="Sup">b</span> Intervals of the Mean Rescue Dose</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="3" valign="top">Study 1<br>
</td>
<td class="Rrule" align="center" valign="top">Dexmedetomidine Hydrochloride Injection<br>            0.5 mcg/kg <br>
</td>
<td class="Rrule" align="center" valign="top"> 134 <br>
</td>
<td class="Rrule" valign="top">
<br>40<br>
</td>
<td class="Rrule" valign="top">
<br>37 (27, 48) </td>
<td class="Rrule" valign="top">
<br>1.4 (1.7) </td>
<td class="Rrule" valign="top">
<br>-2.7 (-3.4, -2) </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">Dexmedetomidine Hydrochloride Injection 1 mcg/kg<br>
</td>
<td class="Rrule" valign="top">
<br>129 </td>
<td class="Rrule" valign="top">54 <br>
</td>
<td class="Rrule" valign="top">
<br>51 (40, 62) </td>
<td class="Rrule" valign="top">
<br>0.9 (1.5) </td>
<td class="Rrule" valign="top">
<br>-3.1 (-3.8, -2.5) </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">placebo<br>
</td>
<td class="Rrule" align="center" valign="top">63<br>
</td>
<td class="Rrule" align="center" valign="top"> 3<br>
</td>
<td class="Rrule" align="center" valign="top"> –<br>
</td>
<td class="Rrule" align="center" valign="top">4.1 (3)<br>
</td>
<td class="Rrule" align="center" valign="top">–<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" rowspan="2" valign="top">Study 2<br>
</td>
<td class="Rrule" align="center" valign="top">Dexmedetomidine Hydrochloride Injection 1 mcg/kg<br>
</td>
<td class="Rrule" valign="top">
<br>55 </td>
<td class="Rrule" align="center" valign="top"> 53 <br>
</td>
<td class="Rrule" valign="top">
<br>  39 (20, 57) </td>
<td class="Rrule" valign="top">
<br>1.1 (1.5) </td>
<td class="Rrule" valign="top">
<br>-1.8 (-2.7, -0.9) </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top"> placebo<br>
</td>
<td class="Rrule" align="center" valign="top">50<br>
</td>
<td class="Rrule" align="center" valign="top">14<br>
</td>
<td class="Rrule" valign="top"> –<br>
</td>
<td class="Rrule" align="center" valign="top">2.9 (3)<br>
</td>
<td class="Rrule" align="center" valign="top">–<br>
</td>
</tr>
</tbody></table>
<br><p><span class="Sup">a </span>Based on ITT population defined as all randomized and treated patients. </p>
<br><p><span class="Sup">b </span>Normal approximation to the binomial with continuity correction. </p>
<br><br>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="d7efabc3-9b0b-4c55-9e08-7918632570d1"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Dexmedetomidine Hydrochloride Injection, is a clear, colorless solution available as: </p>
<table border="0" cellpadding="0" cellspacing="0" width="600"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Product</span><br><span class="Bold">No.</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">NDC</span><br><span class="Bold">No.</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold">Strength</span><br>
</td>
<td class="Rrule" valign="top">
<span class="Bold"> </span><br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">462102<br>
</td>
<td class="Rrule" valign="top">63323-421-02<br>
</td>
<td class="Rrule" valign="top">200 mcg (dexmedetomidine)/2 mL<br>100 mcg (dexmedetomidine)/mL<br>
</td>
<td class="Rrule" valign="top">2 mL vial, packaged in trays of 25.<br>
</td>
</tr>
</tbody></table>
<br><p>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</p>
<p>This container closure is not made with natural rubber latex.</p>
<p>Discard unused portion.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="e99912b1-f152-401d-819d-2ebe7d81db33"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Dexmedetomidine Hydrochloride Injection is indicated for short-term intravenous sedation. Dosage must be individualized and titrated to the desired clinical effect.  Blood pressure, heart rate and oxygen levels will be monitored both continuously during the infusion of Dexmedetomidine Hydrochloride Injection and as clinically appropriate after discontinuation.</p>
<ul class="Disc">
<li>When Dexmedetomidine Hydrochloride Injection is infused for more than 6 hours, patients should be informed to report <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> that may occur for up to 48 hours.</li>
<li>Additionally, patients should be informed to report symptoms that may occur within 48 hours after the administration of Dexmedetomidine Hydrochloride Injection such as: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, excessive <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, salt cravings, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or light-headedness.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="cb2d011c-47b9-4d86-b2f8-d6579adac30d"></a><a name="section-17"></a><p></p>
<p class="First"><img alt="FK-logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c1b8eb58-596b-481d-beb6-ba9d2237abf4&amp;name=fk-address.jpg"></p>
<p>451212</p>
<p>Issued: December 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="a3ef356d-aa6a-4d4f-820c-1c1303ae358b"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Dexmedetomidine Hydrochloride 2 mL Vial Label<br></span></p>
<p><span class="Bold">Dexmedetomidine HCl Injection</span></p>
<p><span class="Bold">2</span><span class="Bold">00 mcg (base)per 2 mL  </span></p>
<p><span class="Bold">(100 mcg (base) per mL)</span></p>
<p>For intravenous infusion.</p>
<p><span class="Bold">MUST BE DILUTED</span>.<br>Discard unused portion.</p>
<p><span class="Bold">2 mL</span> Single Use Vial</p>
<p>Rx only</p>
<p><img alt="vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c1b8eb58-596b-481d-beb6-ba9d2237abf4&amp;name=462102-vial.jpg"><br><br> </p>
<p><span class="Bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Dexmedetomidine Hydrochloride 2 mL Vial Tray Label</span></p>
<p><span class="Bold">Dexmedetomidine HCl Injection</span></p>
<p><span class="Bold">200 mcg* per 2 mL</span></p>
<p><span class="Bold">(100 mcg per mL)</span></p>
<p>For intravenous infusion.</p>
<p><span class="Bold">MUST BE DILUTED</span>.<br>Discard unused portion.<br>Preservative free.</p>
<p><span class="Bold">25 x 2 mL</span> Single Use Vials</p>
<p>Rx only</p>
<p> <img alt="tray" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c1b8eb58-596b-481d-beb6-ba9d2237abf4&amp;name=462102-tray.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEXMEDETOMIDINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">dexmedetomidine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-421</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DEXMEDETOMIDINE HYDROCHLORIDE</strong> (DEXMEDETOMIDINE) </td>
<td class="formItem">DEXMEDETOMIDINE</td>
<td class="formItem">100 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem">597 ug  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem">27 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-421-02</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA201072</td>
<td class="formItem">09/18/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi USA, LLC</td>
<td class="formItem"></td>
<td class="formItem">840771732</td>
<td class="formItem">MANUFACTURE(63323-421)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>22aaed57-d1aa-403b-91df-860b947bc50e</div>
<div>Set id: c1b8eb58-596b-481d-beb6-ba9d2237abf4</div>
<div>Version: 1</div>
<div>Effective Time: 20141212</div>
</div>
</div> <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
